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The role of transforming growth factor-b (TGF-b) receptor
complex in the pathogenesis of crescentic
glomerulonephritis (GN) is not clear. To test the hypothesis
that TGF-b signaling plays a crucial role in the development
and progression of crescentic GN by inducing the activation
of extracellular signal-regulated kinase (ERK) and expression
of its target genes, anti-glomerular basement membrane
(GBM) GN was induced in TGF-b type II receptor (TGF-bIIR)
gene heterozygous (TGF-bIIRþ /) C57BL/6J mice and
wild-type animals. GN was initiated in preimmunized mice by
administration of rabbit anti-mouse GBM serum. TGF-bIIR
deficiency was significantly associated with decreased renal
damage at days 14, 21, and 28 after induction of GN: renal
function impairment, proteinuria, proportion of crescents,
glomerular accumulation of periodic acid-Schiff-positive
material, relative cortical interstitial volume, as well as renal
cortical phosphorylation of ERK and plasminogen activator
inhibitor type I (PAI-1) and a2(I) collagen mRNA levels were
significantly decreased in TGF-bIIRþ / mice compared with
wild-type animals. These results provide the first direct
evidence that TGF-bIIR deficiency protects against renal
injury in crescentic GN, possibly by inhibiting the sustained
activation of ERK and PAI-1 and a2(I) collagen gene
expression. Thus, TGF-b signaling appears to play an
important role in the development and progression of
crescentic GN by inducing the ERK activity, and PAI-1 and
a2(I) mRNA expression.
Kidney International (2007) 71, 882–888. doi:10.1038/sj.ki.5002149;
published online 14 February 2007
KEYWORDS: anti-GBM glomerulonephritis; ERK activity; TGF-b signaling;
PAI-1; a2(I) collagen
Experimental anti-glomerular basement memebrane (GBM)
glomerulonephritis (GN) provides a model of a fibrin-
dependent GN, which closely parallels human crescentic GN.
Anti-GBM GN results in activation of renal transforming
growth factor-b (TGF-b) system early after disease
initiation.1
TGF-b exerts its effects through an interaction with the
TGF-b type II receptor (TGF-bIIR) and the type I receptor.2,3
Smad proteins are important signaling transducers from
those receptors to the target genes, such as plasminogen
activator inhibitor type I (PAI-1) and a2(I) collagen.4 PAI-1
is not expressed in normal kidneys, but is upregulated in
human5,6 and experimental7,8 crescentic GN associated with
glomerular fibrin accumulation. Type I collagen is an
interstitial collagen, and is expressed in the lesions of
interstitial fibrosis and crescents in experimental crescentic
GN.9
Extracellular signal-regulated kinase (ERK), the most
readily detectable mammalian mitogen-activated protein
(MAP) kinase, is activated in experimental crescentic GN.10
Whereas the TGF-b receptor transduces the signal through its
serine/threonine kinase activity, the MAP kinase pathways
have been attributed mainly to growth factor stimulation of
protein tyrosine kinases.11 Nontheless, TGF-b activates ERK
in certain cultured cell lines including mesangial cells.12–15
Furthermore, ERK contributes to TGF-b1-induced PAI-114
or a1(I) collagen13 expression via synergistic interaction with
Smads14 in cultured human mesangial cells. For maximal
Smad activation, TGF-b-induced ERK activity to phosphory-
late the linker segments of Smad2/Smad316–18 is required in
mesangial cells.14 Despite this in vitro data, it is even
unknown whether TGF-b induces ERK activation in renal
diseases mediated by TGF-b.
Blockade of TGF-b action by adenovirus-mediated gene
transfer of TGF-bIIR did not prevent the development of rat
anti-GBM GN.19 Blockade of TGF-b signaling in T cells in
Smad7-transgenic mice prevented the development of anti-
GBM GN, only in cases receiving a medium dose of anti-
GBM antibody but not in those with a high-dose antibody.20
Thus far, the role of TGF-b/TGF-bIIR in the development
and progression of crescentic GN is not clearly defined.
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TGF-bIIR gene knockout mice die at embryonic day owing
to hematopoietic and vasculogenetic defects in the yolk sac.21
Thus, using TGF-bIIR gene heterozygous (TGF-bIIRþ /)
mice could be a useful approach in studying the role of TGF-
bIIR in the development and progression of crescentic GN.
We raised the possibility that TGF-bIIR deficiency may
suppress the ERK activation and TGF-b target gene
expression ameliorating the development and progression
of renal injury when anti-GBM GN is induced. To address
this question, we compared the severity of renal lesions, and
renal expression of phosphorylated ERK and PAI-1 and a2(I)
collagen mRNAs between TGF-bIIRþ / and wild-type mice
after the induction of GN.
RESULTS
Clinical characteristics
Injection of nephrotoxic serum induced a significant decrease
in body weight at the end of experiment compared with that
at day 0 in wild-type mice (Po0.05) (Figure 1a). TGF-
bIIRþ / animals, however, showed no significant weight
reduction at the end of experiment except for those
terminated 14 days after induction of GN (Figure 1b).
Injection of nephrotoxic serum induced an increase in
daily proteinuria in both strains. However, wild-type animals
excreted significantly greater amounts of proteinuria than
TGF-bIIRþ / mice at each time experiment (Figure 2a).
Most wild-type animals developed renal failure, whereas
most TGF-bIIRþ / mice maintained normal renal function.
Blood urea nitrogen (BUN) levels in wild-type mice were
significantly higher than those of TGF-bIIRþ / animals at
each time experiment (Figure 2b). Concentrations of plasma
creatinine were also significantly increased in wild-type mice
compared with TGF-bIIRþ / animals 14–28 days after the
induction of GN. At day 7, wild-type mice tended to show
higher plasma creatinine levels than TGF-bIIRþ / animals,
but the difference was not statistically significant (Figure 2c).
Both the wild type and the TGF-bIIRþ / control mice
showed neither proteinuria nor renal dysfunction throughout
the experimental period after injection of rabbit IgG. No
difference was shown between the wild type and TGF-bIIRþ /
control mice in the amounts of proteinuria (1.270.6 vs
1.470.7 mg/day), concentrations of BUN (32.775.9 vs
31.676.8 mg/dl), and the levels of plasma creatinine
(0.670.08 vs 0.570.06 mg/dl).
Pathology
Both the wild type and the TGF-bIIRþ / control mice
showed no histological abnormalities (Figure 3a and b). After
injection of nephrotoxic serum, however, there was a marked
difference in histological severity of GN between both
genotypes. Most glomeruli in the wild-type mice were
abnormal with lesion severity ranging from moderate
mesangial hypercellularity to heavy accumulation of periodic
acid-Schiff (PAS)-positive material and/or the presence of
crescents. Heavy deposits of PAS-positive eosinophilic
material that stained positive for fibrin22 were frequently
present in capillary lumens of wild-type mice showing the
features of fibrin thrombi (Figure 3c). In contrast, TGF-
bIIRþ / mice exhibited either slight mesangial proliferation
or modest glomerular changes with lesser PAS-positive
material and rare crescent formation at each time experiment
(Figure 3d).
The mean percentage of the glomeruli affected by the
crescents was significantly higher in the wild-type mice
compared with TGF-bIIRþ / animals 14–28 days after the
induction of GN (day 14, 53721.2 vs 7.277%; day 21,
58.5723.5 vs 1.471.3%; day 28, 50.5713.4 vs 7.376.9%)
(Po0.05). At day 7, wild-type mice tended to have a higher
percentage of crescents than TGF-bIIRþ / mice (5.275 vs
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Figure 1 | Changes in body weight in wild-type (WT) and TGF-b
type II receptor gene heterozygous (HT) mice after induction of
glomerulonephritis (GN). Body weight was compared between
day 0 and day of termination in (a) WT and (b) HT mice with GN.
Animals were grouped into 7, 14, 21 and 28 according to
experimental days after induction of GN. *Po0.05 vs. day 0.
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Figure 2 | Functional parameters of renal injury in WT and TGF-b type II receptor gene HT mice after induction of GN. The amounts of
(a) daily proteinuria and concentrations of (b) BUN, and (c) plasma creatinine were significantly decreased in HT mice than WT animals with GN.
*Po0.05 vs WT mice.
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1.871.7%), but the difference was not statistically significant
(Figure 4a).
Glomeruli were graded on a scale of 0–4 for PAS-positive
material accumulation. Accumulation of PAS-positive mate-
rial, which includes cell debris, plasma proteins, immuno-
globulin deposits, and fibrin,22 was significantly greater in
wild-type mice compared with TGF-bIIRþ / mice 14–28
(days after the induction of GN (day 14, 2.970.2 (arbitrary
units) vs 0.870.7; day 21, 2.670.8 vs 0.170.1; day 28,
1.871.1 vs 0.670.5) (Po0.05). However, no significant
difference was noted between two groups at day 7 (Figure 4b).
Tubules from the wild-type animals showed focal atrophy
or loss to a variable degree and frequently contained large
protein casts with moderate infiltration of leukocytes or
collagen laydown in interstitium after the induction of
disease (Figure 3e). In contrast, TGF-bIIRþ / mice exhibited
either no abnormalities or modest tubulo-interstitial changes
(Figure 3f). The relative renal cortical interstitial volume
from TGF-bIIRþ / mice was significantly decreased than
wild-type animals 14–28 days after the induction of GN (day
14, 10.573 vs 3.773.1%; day 21, 975.7 vs 0.470.3%; day
28, 13.178.6 vs 2.372.1%) (Po0.05). However, there was
no significant difference in relative interstitial volume
between two groups at day 7 (Figure 4c).
Immunoblot analysis
Between control animals, no significant difference was shown
in renal cortical ERK activities throughout the experimental
period after injection of rabbit IgG. At 14–28 days after the
induction of GN, however, the cortical ERK activity in wild-
type mice was up to sevenfold higher than the TGF-bIIRþ /
animals (Figure 5). At day 7, wild-type mice with GN tended
to show increased ERK activity than the TGF-bIIRþ / mice,
but the difference was not statistically significant (Figure 5).
Real-time quantitative reverse transcription-polymerase
chain reaction
Analyses of renal cortex showed median threshold cycle
(CT)¼ 16.83.71.03 for b-actin, and 18.1771.66 for 18S
rRNA. Although b-actin was reported to be unsuitable as an
internal control in the matrigel-treated cell culture system,23
we validated that it is a good internal control in this
experimental model as it remained constant at all time points
and wild type and TGF-bIIRþ / mice expressed the same
amounts of b-actin. We also validated that 18S rRNA used as
a parallel internal control to b-actin is a good one in this
experiment.
The mRNA content of the renal cortical tissue was
analyzed using the 2DDCT method.24 In the wild-type mice,
PAI-1 mRNA level was significantly increased compared with
the TGF-bIIRþ / mice 7–28 days after the induction of GN.
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Figure 3 | Light microscopic view of kidney in WT and TGF-b
type II receptor gene HT mice 14 days after the induction of GN.
(c) A glomerulus from WT with GN shows heavy deposits of
PAS-positive material in capillary lumens with crescent formation.
(e) Tubules from the WT animals with GN show focally severe atrophy
or loss with infiltration of leukocytes and fibrosis in interstitium. In
contrast, HT mice with GN exhibit only (d) slight mesangial
proliferation and (f) minimal tubulo-interstitial changes. (a) WT and
(b) HT control mice show no abnormal findings. PAS staining, original
magnification x 200 (a, b, e, f); x 400 (c, d).
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Figure 4 | Morphological parameters of renal injury in WT and TGF-b type II receptor gene HT mice after induction of GN. (a) The
proportion of crescents, (b) glomerular scores for PAS-positive material, and (c) relative renal cortical interstitial volume were significantly
decreased in HT mice than WT animals with GN. *Po0.05 vs WT mice.
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The increase was particularly prominent in the wild-type GN
mice at day 14, showing its level up to 130-fold higher than
the TGF-bIIRþ / mice (Figure 6a).
The levels of a2(I) collagen transcript were also signifi-
cantly increased in the wild-type animals when compared
with the TGF-bIIRþ / mice at each time experiment.
Particularly, those in the wild-type GN mice at days 14 and
21 were 15 to 22 times higher than the TGF-bIIRþ / mice
(Figure 6b).
DISCUSSION
This study demonstrates that the severity of renal injury, and
renal ERK activity and PAI-1 and a2(I) collagen mRNA
expression are significantly decreased in the TGF-bIIRþ /
mice than the wild-type animals after induction of anti-GBM
GN. These results suggest that TGF-bIIR plays an important
role in the development and progression of crescentic GN
possibly via ERK activation.
We observed that renal cortical activation of ERK was
significantly decreased in TGF-bIIRþ / mice as compared
with wild-type animals at 14, 21, and 28 days after induction
of GN, suggesting that TGF-b signaling induces a sustained
activation of ERK in anti-GBM GN. Although TGF-b is
known to activate ERK in cultured mesangial cells,12–15 this is
the first study demonstrating that TGF-b signaling increases
ERK activity in renal diseases mediated by TGF-b. In this
study, glomerular ERK activity could not be separately tested
because of the limited sample volume. As yet, a significant
increase in ERK activity was detected in both the cortical
tissue and the glomeruli in rat anti-GBM GN,10 suggesting
that ERK activity in the renal cortex may indirectly reflect
that in the glomeruli in this disease.
In vitro studies have shown that ERK signaling pathway
plays an important role in the control of cellular prolifera-
tion.25 In human glomerulopathies, ERK-mediated prolifera-
tion of mesangial cells and myofibroblasts seems to promote
renal fibrosis and disease progression.26 Activation of ERK
resulted in the worsening of renal disease associated with
severe proliferative response in remnant kidney model.27 In
this regard, activation of ERK in our wild-type GN mice
could induce proliferation of glomerular cells and subsequent
renal damage with crescent formation, whereas decreased
ERK activity in the TGF-bIIRþ / mice might result in the
opposite effects. Bokemeyer et al.10 suggested that infiltrating
macrophages might contribute to the enhanced ERK activity
in rat anti-GBM GN. However, few macrophages showed
ERK activation in human glomerulopathies.26
In this study, renal expression of PAI-1 mRNA was
dramatically decreased in the TGF-bIIRþ / mice than the
wild-type animals particularly at day 14 after induction of
GN. Although overexpression of PAI-1 has been well
established in human5,6 and experimental7,8,28 crescentic
GN, this is the first study demonstrating that activated TGF-b
system upregulates PAI-1 transcript in this disease.
Activation of ERK by TGF-b can result in Smad
phosphorylation and regulate Smad activation.16–18 ERK
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Figure 6 | Renal cortical mRNA expression of PAI-1 and a2(I)
collagen in WT and TGF-b type II receptor gene HT mice after
induction of GN. Using rverse transcriptase, cDNA was synthesized
from total renal cortical RNA. Using the cDNA aliquots, primers for
PAI-1, a2(I), and b-actin, and SYBR Green, real-time PCR was
performed. Data were analysed using the 2DDCT method. Renal
cortical (a) PAI-1 and (b) a2(I) collagen mRNA levels were significantly
increased in WT mice with GN than HT animals. *Po0.05 vs HT mice.
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contributes to the effects of Smad signaling in oxidized low-
density lipoprotein- or TGF-b1-induced PAI-1 expression in
cultured human mesangial cells.14,29 Exceptionally, TGF-b1-
induced nuclear translocation of Smads and their binding to
the rat PAI-1 promoter were not affected by ERK kinase
inhibitors in rat mesangial cells, which might be attributed to
the difference in the PAI-1 promoter sequence between rat
and human gene.15 In this regard, we conjecture that
activated ERK in the wild-type mice with GN could induce
renal PAI-1 gene overexpression through downstream
activation of Smads.
We found that the proportion of crescents and glomerular
accumulation of PAS-positive material were strikingly
decreased in TGF-bIIRþ / mice than the wild-type animals
with GN. Accumulation of fibrin-containing PAS-positive
material within the glomerular tuft leads to an increased
propensity toward crescent formation in anti-GBM GN.22
The plasminogen/plasmin system has important functions in
the fibrinolysis. PAI-1 inhibits the activities of tissue-type and
urokinase-type plasminogen activator. Thus, enhanced fibri-
nolytic activity in association with reduced PAI-1 gene
expression in our TGF-bIIRþ / mice might inhibit the
glomerular accumulation of PAS-positive material and
subsequent crescent formation after the induction of GN.
In this study, a2(I) collagen mRNA expression was
significantly attenuated in the TGF-bIIRþ / mice than the
wild-type animals with GN, suggesting that activated TGF-b
system upregulates a2(I) collagen transcript in crescentic GN.
Similar to PAI-1, TGF-b stimulates a1(I) or a2(I) collagen
expression13,30 in cultured human mesangial cells via
synergistic ERK–Smad interaction.13 Despite these in vitro
data, type I collagen is only present in the lesions of
interstitial fibrosis and crescents in experimental crescentic
GN.9 Another interstitial collagen, type III collagen, was also
identified in the interstitium and crescents, but not in
glomerulus, in human crescentic GN.31 We also observed that
relative renal cortical interstitial volume was significantly
decreased in the TGF-bIIRþ / mice than the wild-type
animals with GN. Altogether, TGF-bIIR seems to play an
important role in interstitial fibrosis in crescentic GN.
TGF-bIIRþ / mice also inhibited the progression of
diabetic renal injury by suppressing the downstream Smad
signaling and subsequent extracellular matrix gene expres-
sion.32 Activation of ERK seems to be related to glomerular
matrix expansion in obese Zucker rats.33 ERK contributes to
the effects of Smad signaling in TGF-b1-induced a1(I) and
a2(I) collagen or PAI-1 expression in cultured human
mesangial cells.13,14,30 Also, TGF-b-induced activation of
Ras/ERK MAP kinase signaling can induce TGF-b1 expres-
sion, thereby amplifying the TGF-b response and inducing
secondary TGF-b responses.34 Altogether, TGF-bIIR defi-
ciency could protect against renal injury in crescentic GN by
inhibiting the ERK activation and subsequent Smad activa-
tion and/or secondary TGF-b responses.
Short-term treatment with neutralizing antibody against
TGF-b,35 antisense oligonucleotide,36 and decorin37 prevents
intrarenal accumulation of extracellular matrix in rats with
acute mesangial proliferative GN induced by a single
injection of anti-Thy-1.1. SB-525334, an inhibitior of the
TGF-b type I receptor, produces significant reductions in
renal PAI-1, a1(I), and a1(III) mRNA expression in rats with
acute puromycin aminonucleoside nephrosis when compared
with vehicle-treated puromycin aminonucleoside nephrosis
controls.38 In this regard, attempts to inhibit the TGF-b
signaling in the early stage of crescentic GN merit further
attention.
In summary, our results indicate that TGF-bIIR deficiency
protects against renal injury in crescentic GN, possibly by
inhibiting the sustained ERK activity and PAI-1 and a2(I)
collagen gene expression. Thus, TGF-b signaling appears to
play a central role in the development and progression of
crescentic GN by inducing the activation of ERK and PAI-1
and a2(I) mRNA expression.
MATERIALS AND METHODS
Animals
Both the TGF-bIIRþ / and wild-type C57BL/6J mice were kindly
donated by Dr Seong-Jin Kim (Laboratory of Cell Regulation and
Carcinogenesis, National Cancer Institute, Bethesda, MD, USA).
TGF-bIIRþ / mice were generated using TGF-bIIR/ embryonic
stem cell lines, as described previously.21,39 TGF-bIIRþ / embryonic
stem cells were injected into blastocysts of each C57BL/6J embryo
and the embryos were implanted into pseudo-pregnant carrier mice.
The resulting chimeric mice were then analyzed, and TGF-bIIRþ /
mice were bred. In our lab, there have been more than 10
backcrosses in the mice used for this experiment to guarantee that
the genetic background of the TGF-bIIRþ / mice is similar to that
of the wild-type mice. The same C57BL/6J mice were used for
backcrossing and for wild type. We found that TGF-bIIRþ / control
mice live as long as wild-type control mice with no sign of
spontaneous renal pathology.32 TGF-bIIRþ / and wild-type mice
were fed standard pellet laboratory chow and provided with water
ad libitum.
Preparation of anti-mouse GBM serum
Rabbit anti-mouse GBM immune serum was produced as described
by Salant and Cybulsky.40 In brief, minced mice kidneys were
sequentially sieved and the glomeruli were collected. After
centrifugation, the pellet was resuspended and sonically disrupted.
A New Zealand White rabbit was immunized with 10 mg of
glomerular sonicates (0.5 ml of the antigen emulsified in complete
Freund’s adjuvant, 1:1) by multiple subcutaneous injections. Finally,
5 mg of glomerular sonicates was injected into the vein of rabbit ear.
The rabbit was bled 10 days after the injection. The rabbit anti-
mouse GBM serum was heat inactivated and filtered through 1.2 mm
filters before each intravenous injection.
Induction of anti-GBM GN
Weight-matched TGF-bIIRþ / or wild-type (TGF-bIIRþ /þ ) mice
(24–37 g) were immunized by subcutaneous injection of 0.2 mg of
rabbit IgG in 0.2 ml of 1:1 emulsion with complete Freund’s
adjuvant. Six days later, GN was induced by an intravenous injection
of rabbit anti-mouse GBM serum (0.1 ml/20 g body weight) through
the tail vein. The intravenous injection was repeated 24 h after the
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first injection. Mice were killed at day 7 (TGF-bIIRþ /þ , N¼ 5;
TGF-bIIRþ /, N¼ 4), day 14 (TGF-bIIRþ /þ , N¼ 6; TGF-bIIRþ /,
N¼ 6), day 21 (TGF-bIIRþ /þ , N¼ 6; TGF-bIIRþ /, N¼ 5), and
day 28 (TGF-bIIRþ /þ , N¼ 3; TGF-bIIRþ /, N¼ 4) after the first
injection of anti-GBM serum. TGF-bIIRþ /þ (N¼ 12) and TGF-
bIIRþ / (N¼ 12) control mice were injected with rabbit IgG alone.
The kidneys were removed under anesthesia with ether.
Evaluation of proteinuria, plasma creatinine, and BUN
Urine was collected during a 24-h period from mice in metabolic
cages. During collection, mice were allowed free access to water, but
food was withdrawn. Urine protein was quantified using bicinch-
oninic acid with bovine serum albumin as a standard. At the end of
the experiment, the mice were exsanguinated (up to 1 ml blood/
mouse) via aortic puncture under ether anesthesia and plasma was
obtained. BUN and plasma creatinine were quantified spectro-
photometrically using commercially available kits (Sigma, St Louis,
MO, USA).
Pathological study
Midline coronal sections of the kidney were fixed overnight in 4%
paraformaldehyde at 41C, embedded in paraffin, and stained with
hematoxylin and eosin or PAS. More than 50 glomeruli were
examined in each mouse. The percentage of glomeruli showing
crescent formation was assessed. Cellular crescent was defined as a
lesion consisting of at least two layers of proliferating epithelial and
inflammatory cells filling part or all of Bowman’s space. PAS-stained
sections were scored in a blinded manner using a semiquantitative
scale according to the content of PAS-positive material within
glomeruli as follows: 0¼ no deposition of PAS-positive material,
1¼ up to one-fourth of the cross-sectional area of the glomerulus
that stained positive, 2¼ one-fourth to half involvement, 3¼ half to
three-fourths involvement, and 4¼ greater than three-fourths
involvement. A minimum of 20 glomeruli was scored per mouse.
Volume density of renal cortical interstitium (Vv(int/cortex)) was
measured in 10 randomly selected areas by the method of point-
counting on the light microscopic sections at a magnification of
 400 using a 100-point, calibrated, eyepiece grid as we have
described previously.41 We only counted the points lying on
interstitial tissue (Pi). Then Vv(int/cortex) was calculated from:
Vvðint=cortexÞ¼
P
Pi
10010 ðmm
3=mm3Þ
Then relative interstitial volume of renal cortex was calculated from:
Relative interstitial volume ð%Þ ¼Vvðint=cortexÞ100
Immunoblot analysis
Renal cortical lysates were electrophoretically resolved using a 10%
polyacrylamide gel in a sodium dodecyl sulfate buffer and then
transferred onto nitrocellulose membranes as described previously.42
The blots were incubated in blocking solution for 1 h and incubated
with rabbit anti-ERK1/2 or anti-phosphorylated ERK1/2 (Cell
Signaling Technology Inc., Beverly, MA, USA) at 41C overnight.
Bound primary antibody was visualized after incubation with
horseradish peroxidase-conjugated secondary antibody using an
enhanced chemiluminescence system kit (Amersham, Arlington
Heights, IL, USA). The intensity of identified bands was quantified
by densitometry analysis.
Real-time quantitative reverse transcription-polymerase
chain reaction
Total RNA was isolated from the renal cortex and used to synthesize
complementary DNA (cDNA) by reverse transcription using reverse
transcriptase premix kit (Bioneer, Daejeon, Korea). Oligonucleotide
primers for linear amplification were as follows: PAI-1 (GeneBank
accession no. M33960), forward 50-ATG AAT TTC CTA GCA GGC
CA–30 and reverse 50-GGC TGT CCA GTG CAT AAT GA-30; a2(I)
collagen (GeneBank accession no. NM007743), forward 50-CCG
TGC TTC TCA GAA CAT CA-30 and reverse 50-GAG CAG CCA
TCG ACT AGG AC-30; b-actin (GeneBank accession no.
NM007393), forward 50-TCC TAA GAG GAG GAT GGT CG-30
and reverse 50-CCT GGG CCA TTC AGA AAT TA-30; 18S rRNA,43
forward 50-TCA AGA ACG AAA GTC GGA GGT T-30 and reverse
50-GGA CAT CTA AGG GCA TCA CAG-30. Using the cDNA mixture
and primers, real-time reverse transcription-polymerase chain
reaction was performed on an ABI Prism 7000 (Applied Biosystems,
Foster City, CA, USA) with SYBR Green polymerase chain reaction
master mix (Takara Korea Biomedical, Seoul, Korea). Two internal
controls, b-actin and 18S rRNA, were used in parallel to detect any
systematic bias. Cycle conditions were as follows: after an initial hold
of 10 s at 941C, the samples were cycled 40 times at 941C for 5 s and
601C for 31 s. Each sample was tested in triplicate and repeated
twice. The mRNA content of the renal cortical tissue was analyzed
using the 2DDCT method.24 The primer for b-actin was cDNA-
specific, whereas the assay for 18S rRNA might detect contaminating
genomic DNA.44 In this regard, we compared reverse transcriptase-
negative with transcriptase-positive tissues. A DCT of X10 was
observed corresponding to a negligible contamination of genomic
DNA below 0.1%.
Statistics
Results were presented as mean7s.d. The significance of differences
among three or four groups was assessed using analysis of variance.
Results between two groups were analyzed by Wilcoxon’s rank sum
test. A Po0.05 was considered significant.
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